Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.